Janssen, LP
Janssen, LP
Explore linked clinical trials.23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04071457 | |
| Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-17 | NCT02436707 | |
| Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell acute lymphoblastic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-15 | NCT05289687 | |
| 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-09-15 | NCT03004287 | |
| Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-08-13 | NCT04113018 | |
| CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study | Extramedullary Myeloma | Active, not recruiting | Phase 1 | 2026-07-28 | NCT05666700 | |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-27 | NCT01760005 | |
| Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-06-30 | NCT06015724 | |
| Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC) | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2026-05-27 | NCT03848052 | |
| Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-05-12 | NCT04263480 | |
| Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, extramedullary plasmacytoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-04-20 | NCT04166565 | |
| Computerized Decision Support to Prevent Stroke in Atrial Fibrillation | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, stroke disorder, vascular disorder | Not yet recruiting | Not applicable | 2026-02-25 | NCT06355986 | |
| National Register of Actionable Mutations | Solid Tumours in Advanced Stages | Active, not recruiting | Not stated | 2026-01-30 | NCT05918666 | |
| European Myeloma Network (EMN) Sample Project | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell leukemia, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2025-12-03 | NCT06237803 | |
| Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2025-11-26 | NCT03734198 | |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, lung disorder, mycobacterial infectious disease, pulmonary tuberculosis, respiratory system disorder, respiratory tract infectious disorder, tuberculosis | Recruiting | Phase 2 | 2025-10-06 | NCT06114628 | |
| Brigham and Women's Rheumatoid Arthritis Sequential Study | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Active, not recruiting | Not stated | 2025-09-26 | NCT01793103 | |
| Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Active, not recruiting | Not stated | 2025-09-18 | NCT06019676 | |
| Real-life Management of Patients Eligible for CAR-T Cell Therapy | Hemopathy | Recruiting | Not stated | 2025-04-10 | NCT06369389 | |
| Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over Time | Telomere Length in Healthy Controls | Enrolling by invitation | Not stated | 2025-03-25 | NCT01982890 | |
| Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Active, not recruiting | Phase 2 / Phase 3 | 2025-02-24 | NCT03941132 | |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | neoplasm | Recruiting | Phase 2 | 2024-04-25 | NCT03767075 | |
| The Drug Rediscovery Protocol (DRUP Trial) | cancer, neoplasm | Recruiting | Phase 2 | 2024-01-24 | NCT02925234 |